![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Prevalence, Treatment, and Comorbidities of Hepatitis C Infection (HCV) Among Patients With Commercial and Medicaid Insurance
|
|
|
Reported by Jules Levin
DDW May 18-21 2013 Orlando Florida
EASL: Direct and indirect cost burden is higher in HCV infection compared with a matched non-HCV infected cohort in a privately-insured population - (05/07/13)
EASL: Patient characteristics and utilization of protease inhibitors in hepatitis C virus (HCV) patients in a large payer database - (05/07/13)
Jennifer M Griffith, PharmD1, Woodie M Zachry, III, PhD1, Kathleen Lang, PhD2, Christine Nichols, BA2, Lakshmi P Kandukuri1, Oscar A Hayes, MS1
1AbbVie Inc., North Chicago, Illinois, United States; 2Boston Health Economics, Inc., Waltham, Massachusetts, United States
![DDW1.gif](../images/052113/052113-2/DDW1.gif)
![DDW2.gif](../images/052113/052113-2/DDW2.gif)
![DDW3.gif](../images/052113/052113-2/DDW3.gif)
![DDW4.gif](../images/052113/052113-2/DDW4.gif)
![DDW5.gif](../images/052113/052113-2/DDW5.gif)
![DDW6.gif](../images/052113/052113-2/DDW6.gif)
![DDW7.gif](../images/052113/052113-2/DDW7.gif)
![DDW8.gif](../images/052113/052113-2/DDW8.gif)
![DDW9.gif](../images/052113/052113-2/DDW9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|